17,377 Shares in Smith & Nephew SNATS, Inc. $SNN Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 17,377 shares of the medical equipment provider’s stock, valued at approximately $1,090,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SNN. Clearstead Trust LLC acquired a new position in shares of Smith & Nephew SNATS during the second quarter valued at $25,000. Addison Advisors LLC bought a new stake in Smith & Nephew SNATS in the 2nd quarter valued at about $43,000. Allworth Financial LP acquired a new position in Smith & Nephew SNATS during the 2nd quarter valued at about $48,000. Garner Asset Management Corp acquired a new position in Smith & Nephew SNATS during the 4th quarter valued at about $27,000. Finally, Arax Advisory Partners grew its position in Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analysts Set New Price Targets

SNN has been the topic of a number of recent analyst reports. Barclays cut Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Canaccord Genuity Group decreased their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. Zacks Research lowered Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Finally, Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $29.29 on Monday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $30.32 and a 200 day moving average price of $31.85. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.